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Abstract 
Background 
Autonomic dysfunction is common in the later stages of Parkinson's disease (PD), 
but less is known about its presence and severity in early disease. 
Objective 
To analyze features of autonomic dysfunction in recent onset PD cases, and their 
relationship to motor severity, medication use, other nonmotor symptoms (NMS), 
and quality-of-life scores. 
Methods 
Detailed patient-reported symptoms of autonomic dysfunction were assessed in a 
multicenter cohort study in PD cases that had been diagnosed within the preceding 
3.5 years. 
Results 
There were 1746 patients (1132 males, 65.2%), mean age 67.6 years (SD 9.3), 
mean disease duration 1.3 years (SD 0.9), mean Movement Disorder Society Unified 
Parkinson's Disease Rating Scale motor score 22.5 (SD 12.1). Orthostatic symptoms 
were reported by 39.6%, male erectile dysfunction by 56.1%, and female 
anorgasmia by 57.4%. Sialorrhea was an issue in 51.4% of patients, constipation in 
43.6%, and dysphagia in 20.1%. Autonomic features increased with higher modified 
Hoehn and Yahr stages (P < 0.001). The severity of autonomic dysfunction was 
associated with the postural instability gait difficulty motor phenotype [β-coefficient 
1.7, 95% confidence interval (CI) 0.7, 2.6, P < 0.001], depression (β-coefficient 4.1, 
CI 3.0, 5.2, P < 0.001), and excess daytime sleepiness (β-coefficient 3.1, CI 1.9, 
4.2, P < 0.001). Dopamine agonists were the only drug class associated with greater 
autonomic dysfunction (P = 0.019). The severity of autonomic dysfunction strongly 
correlated with the presence of other NMS (ρ = 0.717, P < 0.001), and with poorer 
quality-of-life scores (ρ = 0.483, P < 0.001). 
Conclusions 
Autonomic dysfunction is common in early PD. Autonomic dysfunction correlates 
with the presence of other NMS, and with worse quality of life. 
 Introduction 
Autonomic dysfunction is well recognized in Parkinson's disease (PD), and is often 
multifaceted.[1] The symptoms of autonomic dysfunction in PD range from 
orthostatic intolerance to vasomotor dysfunction, secretomotor problems, 
gastroparesis, diarrhea, constipation, bladder disturbances, pupillary and focusing 
abnormalities causing visual blurring, and sexual dysfunction. Dysautonomia is 
common in the later stages of PD, with disease progression and medication side 
effects.[2] Prominent autonomic features in recent onset cases are classically 
regarded as a “red flags” for multiple system atrophy (MSA), and are highlighted as 
raising diagnostic doubt for PD. Specifically, orthostatic hypotension and urinary 
incontinence in the first 5 years are suggestive of MSA.[3] However, the accuracy of 
differentiating PD from MSA is low in early disease[4] and sometimes even in later 
disease.[5] This could reflect a failure to recognize the cardinal distinguishing 
features, but might also result from significant overlap in the autonomic 
manifestations of the two disorders, which is likely because the underlying 
distribution and type of pathology (α-synuclein accumulation) has significant 
similarities.[6] 
We explored the prevalence, range, and severity of autonomic symptoms in a cohort 
of cases recently diagnosed with PD. We also examined the extent to which cases 
with unusual or atypical features exhibited differences in autonomic function from 
those without such features. We hypothesized that the presence of atypical features 
would be reflected in greater levels of autonomic dysfunction. 
Methods 
The Tracking Parkinson's study is a large prospective, observational, multicenter 
project in the United Kingdom (UK). Patients were recruited with a clinical diagnosis 
of PD, fulfilling UK Brain Bank criteria[7] and supported by structural and/or 
functional neuroimaging performed when the diagnosis was not firmly established 
clinically. Both drug-naïve and treated patients, aged 18 to 90 years, were eligible. 
Recent onset cases (diagnosed with PD in the preceding 3.5 years) were recruited 
between February 2012 and May 2014. Patients were not enrolled if they had severe 
comorbid illness, other degenerative forms of parkinsonism including clinician-
diagnosed MSA, or parkinsonism attributable to significant cerebrovascular disease. 
Patients with drug-induced parkinsonism were excluded, but drug-unmasked PD was 
allowed if justified by abnormal functional dopaminergic imaging. Patients whose 
diagnosis was changed from PD during a 6-month follow-up were excluded from 
analysis. 
Any features that were potentially unusual for PD were noted at recruitment and 
during follow-up, including atypical signs or symptoms, either a static or a rapidly 
progressive disease course, and a poor response to dopaminergic medication. 
Cases with any of these potentially atypical features, and cases with missing data, 
were excluded from the main analysis (Figure 1). However, an additional analysis 
was performed to compare autonomic features, in cases with possible atypical 
features, to the entirely typical PD cases. 
 Figure 1. 
Patient recruitment to this study. The main analysis of autonomic features was 
performed in cases without features that might be atypical for Parkinson's disease. 
Additional analysis was undertaken comparing autonomic features in those with and 
without atypical features. PD, Parkinson's disease; PSP, progressive supranuclear 
palsy; MSA, multiple system atrophy; SCOPA-AUT, scales for outcomes in 
Parkinson's disease—autonomic symptoms. 
The study was performed in accordance with the Declaration of Helsinki. Parkinson's 
UK, the national patient care and research organization, provided research funding 
for this project. 
Seventy-two sites in the UK, which provide secondary care treatment for PD patients 
as part of the UK National Health Service (NHS) (or linked academic institutions), 
participated, with ethics committee and research and development approvals, and 
written patient informed consent. 
Demographic characteristics, diagnostic features at presentation, medication history, 
dietary history, modified Hoehn and Yahr (H&Y) staging,[8] Movement Disorder 
Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) scores,[9] and 
motor “on” or “off” state in the clinic were recorded. The Scale for Outcomes in 
Parkinson's disease for Autonomic Symptoms (SCOPA-AUT), a 23-item validated 
questionnaire, was used to assess features of autonomic dysfunction[10] in six 
domains: gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillomotor, 
and sexual, resulting in a total score out of 69. Patients completed this questionnaire 
on paper. Results were tabulated against the H&Y stage, considering mild disease 
as grade 1 or 1.5, moderate as grade 2 or 2.5, and more severe as grade 3 or 
higher. The nonmotor symptom severity scale (NMSS)[11] and PD 8-item quality-of-
life Questionnaire (PDQ-8)[12] were also scored. Montreal cognitive assessment 
(MoCA) test scores were adjusted for years of education. Sleep problems were 
assessed with the PD sleep scale (PDSS, higher PDSS scores are associated with 
less sleep disturbance),[13] Epworth Sleepiness scale (ESS)[14] and rapid eye 
movement sleep (REM) sleep behavior disorder scale.[15] Hyposmia was defined as 
Sniffin' Stick score at or below the 10th centile[16] or University of Pennsylvania 
Smell Identification Test score (British version) at or below the 15th centile, corrected 
for age and sex.[17] Presence of low mood and depression was assessed using the 
Leeds Anxiety and Depression Scale (LADS) with a cut-off score >6.[18] Daily 
antiparkinsonian medication doses [in levodopa (l-dopa) equivalent units] were 
calculated using an established formula.[19] Orthostatic hypotension was defined by 
2 established methods, based on a blood pressure fall from lying flat to standing for 
3 minutes of (a) ≥20 mm Hg systolic or 10 mm Hg diastolic,[20] and (b) ≥30 mm Hg 
systolic or 15 mm Hg diastolic.[3] 
Statistical Analysis 
Spearman rank order correlation was used to assess the relationship between 
baseline SCOPA-AUT score (in those answering >75% of questions) and baseline 
motor, nonmotor and quality-of-life scores. Multiple linear regression was performed 
to determine the influence of H&Y staging on autonomic scores. Logistic regression 
was used when outcomes were binary, ordinal logistic regression (also called a 
proportional odds model) when outcomes were ordinal, and multinomial logistic 
regression when the motor subtype was outcome with tremor dominant as the 
baseline category. When exposures are categorical, as in the H&Y stage, we 
calculated both heterogeneity P values across all groups and a linear trend P value. 
For examining SCOPA-AUT domains a linear regression approach was used when 
there were >10 categories and ordinal logistic regression was used for ≤10 
categories. The proportional odds assumption in ordinal logistic regression was 
tested and relaxed to a partial proportional odds model in which a variable did not 
meet the assumption. The linearity of continuous confounders (such as age and 
disease duration) was tested using fractional polynomials in univariate models and 
then was transformed if they showed evidence of nonlinearity. P values were 2-
tailed, significance was set at P < 0.05, and STATA (version 13, StataCorp, College 
Station, TX) was used. 
Results 
Of 2006 cases recruited, 31 were excluded because of a change in diagnosis or 
disease duration greater than 3.5 years, 61 had missing detail for autonomic 
features, and 168 had one or more possible unusual or atypical features for PD 
(Figure 1). The main analysis dataset was therefore 1746 patients (1132 males, 
65.2%), mean age 67.6 years (SD 9.3), mean disease duration 1.3 years (SD 0.9), 
mean MDS UPDRS 3 score 22.5 (SD 12.1), mean LEDD 294 mg (SD 205), and 
mean SCOPA-AUT score 11.7 (SD 7.0). Considering motor score assessments, 
1624 patients had their “on–off” state recorded, of whom 1494 (92.0%) were in the 
“on” state, and 44 of the 130 in the “off” state (33.8%) were drug naïve, meaning that 
86 of the 1624 cases (5.3%) were in an “off” state when assessed and while on 
prescribed antiparkinsonian medication. The SCOPA-AUT score was significantly 
higher in relation to more advanced H&Y motor stages (P < 0.001; Table 1). Other 
demographic characteristics are shown in Table 1. 
Table 1. Demographic and Clinical Features in Recent Onset Parkinson's Disease 
8 cases with missing H&Y status are not shown; data are presented as mean and standard deviation 
or percentage.  
LEDD= levodopa equivalent daily dose, UPDRS 3= Movement Disorder Society Unified Parkinson’s 
disease rating scale Part 3, PIGD= postural instability and gait difficulty, SCOPA-AUT= Scale for 
Outcomes in Parkinson’s Autonomic symptoms 
 
  Hoehn and Yahr stage   
Variable Total 
N=1738 
1 
N=855 
2 
N=783 
3+ 
N=100 
Heterogeneity 
p  
value 
Trend p 
value 
Age (y) 67.6 (9.3) 66.1 (9.2) 68.7 (9.0) 71.8 (9.1) <0.001a <0.001a 
Age at diagnosis (y) 66.3 (9.2) 64.9 (9.2) 67.3 (9.0) 70.3 (9.1) <0.001a <0.001a 
Duration (y) 1.3 (0.9) 1.2 (0.9) 1.4 (0.9) 1.4 (1.0) <0.001b <0.001b 
Male sex 1132  
(65.1%) 
539 
(63.0%) 
540 
(69.0%) 
53 
(53.0%) 
0.001c 0.88c 
  Drug naïve 168  
(9.7%) 
108 
(12.6%) 
56  
(7.2%) 
4  
(4.1%) 
0.007 d 0.001d 
LEDD (mg) 294 (205) 264 (208) 320 (202) 353 (158) <0.001d <0.001d 
UPDRS 3 22.5  
(12.1) 
16.8 
 (8.8) 
26.4  
(11.3) 
40.1 
(13.7) 
<0.001d <0.001d 
Motor Subtype 
    Tremor dominant 
 
763  
(46.9%) 
 
414 
(51.7%) 
 
339 
(46.2%) 
 
10 
(10.8%) 
 . 
    PIGD 652  
(40.1%) 
273 
(34.1%) 
306 
(41.7%) 
73 
(78.5%) 
<0.001d <0.001d 
    Indeterminate 212  
(13.0%) 
114 
(14.2%) 
88  
(12.0%) 
10 
(10.8%) 
0.018d 0.45d 
Orthostatic 
hypotensione 
 
283  
(16.8%) 
137  
(16.6%) 
127  
(16.5%) 
19  
(20.4%)  
 
0.58d 0.51d 
SCOPA-AUT total 11.7 (7.0) 10.7 (6.2) 12.7 (7.6) 13.5 (6.9) <0.001d <0.001d 
Symptoms of autonomic dysfunction were present in all six domains of the SCOPA-
AUT questionnaire, but to varying degrees (Table 2). Those with more advanced 
motor stages of disease reported significantly more of the following features, whether 
considering the heterogeneity or trend P values: sialorrhea, constipation, incomplete 
bladder emptying, lightheaded when standing up, lightheaded after standing for 
some time, nighttime sweating, and cold intolerance (Tables 2 and 3). Hyperhidrosis 
during the day was less likely (<20% of cases) than hyperhidrosis during the night 
(nearly 30%). Only 11.1% of patients who reported syncope had an objective drop in 
blood pressure exceeding 30/15 mm Hg, whereas 24.4% of those who reported 
syncope had a blood pressure drop exceeding 20/10 mm Hg. There was a weakly 
positive correlation of sialorrhea with both dysphagia (ρ = 0.126, P < 0.001) and with 
swallowing/choking (ρ = 0.157, P < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Gastrointestinal and Urinary Disturbance in Relation to Motor Severity 
Grading in Recent Onset Parkinson's Disease (% with an Item Score ≥1) 
  Hoehn and Yahr stage   
Trend p 
valuea 
Variable Total 
N=1738 
1 
N=855 
2 
N=783 
3+ 
N=100 
Hetero-
geneity 
p valuea 
Gastrointestinal domain 1437 
(83.7%) 
687 
(81.1%) 
659 
(85.6%) 
91 
(91.0%) 
0.091 0.033 
 
Swallowing/choking  421  
(24.3%) 
199 
 (23.3%) 
190 
(24.3%) 
32 
(32.0%) 
0.22 0.21 
Sialorrhea  891  
(51.4%) 
387  
(45.3%) 
448 
(57.5%) 
56 
(56.0%) 
0.003 0.002 
Dysphagia  349  
(20.1%) 
168 
 (19.7%) 
156 
(19.9%) 
25 
(25.0%) 
0.62 0.74 
Early abdominal fullness  361  
(20.8%) 
164  
(19.2%) 
168 
(21.5%) 
29 
(29.0%) 
0.095 0.035 
Constipation  755  
(43.6%) 
335  
(39.2%) 
362 
(46.5%) 
58 
(58.0%) 
0.003 <0.001 
Straining for defecation  1017  
(58.7%) 
470  
(55.1%) 
486 
(62.4%) 
61 
(61.0%) 
0.12 0.12 
Fecal incontinence  125  
(7.2%) 
59  
(6.9%) 
56  
(7.2%) 
10 
(10.0%) 
0.78 0.75 
Urinary domain 1654  
(96.6%) 
815  
(96.6%) 
746 
(96.8%) 
93 
(95.9%) 
0.85 0.74 
  
Urinary urgency  707  
(40.8%) 
329  
(38.6%) 
333 
(42.7%) 
45 
(45.5%) 
0.72 0.48 
Urinary incontinence  500  
(28.8%) 
234 
 (27.4%) 
228 
(29.2%) 
38 
(38.0%) 
0.57 0.41 
Incomplete emptying  739 
 (42.6%) 
342  
(40.0%) 
340 
(43.5%) 
57 
(57.6%) 
0.011 0.016 
Weak stream of urine  717 
 (41.4%) 
334  
(39.1%) 
339 
(43.5%) 
44 
(44.9%) 
0.59 0.30 
Frequency  1371  
(79.1%) 
679  
(79.6%) 
617 
(79.0%) 
75 
(75.0%) 
0.71 0.69 
Nocturia  1518 
 (87.5%) 
736  
(86.5%) 
693 
(88.5%) 
89 
(89.0%) 
0.85 0.63 
8 cases with missing H&Y status are not shown  
a Adjusted for age, sex and disease duration 
 
 Table 3. Cardiovascular, Thermoregulatory, Pupillomotor, and Sexual Disturbance in 
Relation to Motor Severity Grading in Recent Onset Parkinson's Disease (% with an 
Item Score ≥1) 
8 cases with missing H&Y status are not shown  
  Hoehn and Yahr stage   
Variable Total 
N=1738 
1 
N=855 
2 
N=783 
3+ 
N=100 
Hetero-
geneity 
p valuea 
Trend p 
value a 
Cardiovascular domain 680  
(39.6%) 
315  
(37.1%) 
313 
(40.4%) 
52 
(54.7%) 
0.007 0.005 
 
Lightheaded when 
standing up  
580  
(33.6%) 
265  
(31.1%) 
270 
(34.8%) 
45 
(46.4%) 
0.007 0.004 
Lightheaded when 
standing for some time  
414  
(23.9%) 
187  
(21.9%) 
191 
(24.4%) 
36 
(36.7%) 
0.011 0.006 
Syncope  48 
 (2.8%) 
18  
(2.1%) 
26 
 (3.3%) 
4  
(4.0%) 
0.30 0.14 
Thermoregulatory domain 1174  
(68.0%) 
563  
(66.1%) 
539 
(69.5%) 
72 
(72.0%) 
0.19 0.078 
 
Hyperhidrosis during the 
day  
333  
(19.2%) 
162  
(19.0%) 
149 
(19.1%) 
22 
(22.0%) 
0.21 0.088 
Hyperhidrosis during the 
night  
516 
 (29.7%) 
242 
 (28.3%) 
236 
(30.2%) 
38 
(38.0%) 
0.04 0.016 
Cold intolerance  804  
(46.4%) 
360  
(42.2%) 
395 
(50.7%) 
49 
(49.0%) 
0.003 0.006 
Heat intolerance  487  
(28.0%) 
244  
(28.6%) 
204 
(26.1%) 
39 
(39.0%) 
0.059 0.33 
Pupillomotor domain       
Oversensitive to bright 
light  
485  
(28.0%) 
226  
(26.5%) 
229 
(29.2%) 
30 
(30.3%) 
0.57 0.40 
 
Sexual domain 711  
(63.0%) 
365  
(61.9%) 
315 
(63.6%) 
31 
(72.1%) 
0.76 0.73 
 
Men: erection problem  513  
(56.1%) 
238  
(51.5%) 
254 
(60.3%) 
21 
(65.6%) 
0.21 0.085 
Men: ejaculation problem  393  
(45.9%) 
181  
(41.6%) 
197 
(50.4%) 
15 
(50.0%) 
0.14 0.099 
Women: vaginal 
lubrication  
144  
(48.5%) 
88  
(53.0%) 
48 (41.4%) 8  
(53.3%) 
0.081 0.12 
Women: problem with 
orgasm  
166  
(57.4%) 
99 
 (61.9%) 
59 (51.3%) 8  
(57.1%) 
0.17 0.12 
a Adjusted for age, sex and disease duration (except gender specific sexual domain not adjusted for 
sex) 
 
 
 
 
 
A substantial number of patients (33.9%) marked “not applicable” for one or both of 
the sexual items (in 24.9% of males and 50.8% of females), and such cases were 
older at the time of assessment and had an older age at diagnosis compared to the 
other patients (P < 0.001 for age and both genders). 
The presence of depression (P < 0.001), REM sleep behavior disorder (P < 0.001), 
and the postural instability gait difficulty phenotype (P < 0.001) correlated with 
SCOPA-AUT scores (Table 4). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Autonomic Severity in Relation to Key Motor and Nonmotor Categorized 
Variables in Recent Onset Parkinson's Disease 
  SCOPA-AUT score   
 Number 
(%) 
Mean          
(SD) 
Unadjusted 
Beta  
(95% CI) 
 p 
value 
Adjusted a  
Beta  
(95% CI) 
Adjusted 
p valuea 
Hyposmia 
 
699 
(75.3%) 
11.6 
 (6.8) 
-0.0 
 (-1.1, 1.0) 
0.95 0.0  
(-1.0, 1.1) 
0.94 
Depression 
 
227 
(21.3%) 
16.0  
(8.2) 
5.5 
 (4.6, 6.5) 
<0.001 4.1  
(3.0, 5.2) 
<0.001 
RBD 485 
(46.3%) 
13.5 
 (7.4) 
3.5  
(2.7, 4.4) 
<0.001 1.9  
(1.0, 2.8) 
<0.001 
Epworth 
sleepiness 
197 
(18.5%) 
15.7  
(8.4) 
4.9 
 (3.9, 6.0) 
<0.001 3.1  
(1.9, 4.2) 
<0.001 
Motor subtype 
Tremor          
dominant 
 
 
487 
(48.0%) 
 
 
10.1  
(6.5) 
 
 
 
0 
(reference) 
  
 
0  
(reference) 
 
 PIGD 386 
(38.0%) 
13.8 
 (7.4) 
3.7  
(2.8, 4.6) 
<0.001 1.7  
(0.7, 2.6) 
<0.001 
Indeterminate 142 
(14.0%) 
11.5  
(6.1) 
1.4 
 (0.1, 2.7) 
0.030 0.3 
 (-1.1, 1.6) 
0.71 
Cognition 
    Normal 
 
776 
(77.1%) 
 
11.3  
(6.9) 
 
 
0 
(reference) 
  
0  
(reference) 
 
    MCI 114 
(11.3%) 
12.6  
(6.6) 
1.3  
(-0.0, 2.7) 
0.055 0.6  
(-0.9, 2.0) 
0.44 
    Dementia 116 
(11.5%) 
13.4  
(7.7) 
2.2  
(0.8, 3.5) 
0.002 0.4  
(-1.1, 1.9) 
0.59 
SCOPA-AUT= Scales for Outcomes in Parkinson's Disease-Autonomic symptoms, SD= standard 
deviation, CI= confidence interval, RBD= REM sleep behaviour disorder, PIGD= postural instability 
gait difficulty, MCI= mild cognitive impairment.  
a Adjusted for age, sex, disease duration and each of the non-motor features 
 
 
 
Patients who were diagnosed with PD at study entry but who had atypical features 
had significantly higher MDS UPDRS 3 scores (P < 0.001) compared to those 
without any atypical features, but there were no significant differences in age or 
disease duration (Table S1). Patients with atypical features were less likely to have 
the tremor dominant subtype (P = 0.020), more likely to report gastrointestinal 
symptoms (P = 0.016) as well as urinary dysfunction (P < 0.001), and they had 
higher total SCOPA-AUT scores (P = 0.008) (Table S1). Orthostatic hypotension with 
a drop of more than 30/15 mm Hg was present in 6.8% of cases with entirely typical 
PD, whereas an additional 10% of these typical PD cases fulfilled the less stringent 
criteria (20/10 mm Hg) (Table S1). There was no significant difference in the 
proportion of cases with orthostatic hypotension by either criterion, when comparing 
typical PD cases to the PD cases with possibly atypical features. There was a no 
correlation of orthostatic hypotension with ESS total score (ρ = 0.032, P = 0.20) or 
PDSS total scores (ρ = −0.018, P = 0.47), and the correlation with MoCA total score 
was negligible (ρ = −0.053, P = 0.037). 
The majority of our patients were using l-dopa–based medication (61.1%), 34.2% 
were using dopamine agonists, and 27.3% were on monoamine oxidase type B 
inhibitors. Very few (1.3%) were on central anticholinergics. Other medications with 
potential to cause postural hypotension, including diuretics, β-blockers, calcium 
channel blockers, angiotensin converting enzyme inhibitors, α-blockers, nitrates, 
peripheral vasodilators, centrally acting antihypertensives, and angiotensin receptor 
blockers, were used by 38.6%. Among the antiparkinsonian drug classes, only the 
use of dopamine agonists was associated with higher SCOPA-AUT scores (β 
coefficient 1.3, CI 0.2, 2.4, P = 0.019) after appropriate adjustment for age, sex, and 
disease duration (Table S2). 
There was a positive correlation between the presence of autonomic symptoms and 
motor severity based on MDS UPDRS part 3 scores (ρ = 0.207, P < 0.001) as well 
as the presence of sleep disturbance based on PDSS scores (ρ = −0.487, P < 0.001) 
and other nonmotor symptoms (NMS) based on NMSS scores (ρ = 0.717, P < 
0.001). SCOPA-AUT scores also correlated positively with quality-of-life scores 
based on PDQ 8 (ρ = 0.483, P < 0.001). Correlation of SCOPA-AUT total score 
against disease duration was weak (ρ = 0.114, P< 0.001). Cognitive scores showed 
a weakly negative correlation with SCOPA-AUT scores (ρ = −0.119, P < 0.001) 
(Table S3). 
In the 168 drug-naïve cases, SCOPA-AUT scores were lower at 9.5 (5.8), and were 
higher with more advanced H&Y stage, P < 0.001 (Table S4). Depression was 
significantly correlated (P = 0.003) with SCOPA-AUT scores (Table S5), and there 
were also significant relationships between total SCOPA-AUT scores and NMSS (ρ 
= 0.682, P < 0.001), PDSS (ρ = −0.588, P < 0.001), PDQ8 (ρ = 0.474, P < 0.001), 
and MDS UPDRS 3 (ρ = 0.230, P = 0.021) scores (Table S6). 
Discussion 
In this study, we show that symptoms of autonomic dysfunction are common at an 
average PD duration of slightly more than 1 year. The total SCOPA-AUT scores at 
this early stage were around seven points lower than in cases with an average 
disease duration of around 10 years, and around three points higher than that of 
matched controls.[10, 21] Within our cohort, a more advanced motor stage was 
accompanied by a higher autonomic symptom burden, which was also found in two 
previously published studies of PD at a longer disease duration.[2, 10] One previous 
study did not document such differences in autonomic disturbance between mild and 
moderate motor PD stages, but did show greater autonomic disturbance at more 
advanced stages (H&Y 4 and 5).[21] However, the size of that study was a quarter of 
our study size, and patients were approximately 6.5 years younger, which could 
explain the differences. 
The relative proportions of symptoms in different domains of autonomic function in 
our study are similar to the PROPARK study.[21] In that study, syncope affected 4% 
of 420 patients at around 10 years of disease duration, being only 2% among H&Y 1 
and 2 patients,[21] which is similar to the 2.8% figure in our series at 1.3 years' 
duration, suggesting that this feature is partly related to stage and disease duration, 
but generally the prevalence of this symptom is low. In contrast, urinary incontinence 
was present in 51% of patients at 10 years' duration (and 43% at H&Y 1 and 2),[21] 
compared to 28.8% in our study, suggesting that this problem becomes more 
common with increasing PD disease duration. 
One recurrent aspect in assessing autonomic symptoms relates to sexual 
dysfunction, which, as in our study, is often the main source of missing data.[21] 
Whether or not the choice of the “not applicable” option for sexual items by patients 
reflects earlier loss of autonomic function, relates to the personal and sensitive 
nature of the subject, or is for reasons of sexual inactivity as a result of other 
influences, the reason is difficult to determine from the questionnaire, and this 
deserves further study. 
Sleep disorders are common in PD and some sleep disorders such as REM sleep 
behavior disorder can predate the presenting motor symptoms of PD. The correlation 
we identified between sleep problems and autonomic symptoms confirms previous 
findings among 135 PD patients at a mean disease duration of 5.3 years, in which 
worse SCOPA-AUT scores were also associated with worse sleep quality.[2] Our 
finding that the ESS and the RBDSQ were both significant independent predictors of 
autonomic severity (even after adjusting for age, sex, and disease duration) is also 
consistent with this.[2] 
We found that the use of dopamine agonists was associated with more autonomic 
dysfunction, but there was no such association with other antiparkinsonian drug 
classes, or when comparing treated to untreated patients. Comparison with a 
previous study, which reported greater autonomic symptom severity in “treated” 
compared to “untreated” patients, is difficult because our definition was of entirely 
drug-naïve patients whereas their patients were defined as not taking dopamine 
replacement therapy (but this definition allowed selegiline and amantadine).[21] 
Similarly, comparisons with another study that showed no correlation between 
SCOPA-AUT and antiparkinsonian medication are difficult, because that study of 154 
patients included around one-fifth of cases with either MSA or progressive 
supranuclear palsy (PSP),[22] and included patients that were on average 9 years 
younger than our patients, with disease duration that was 5 years longer. Our results 
are therefore novel in identifying an association of autonomic dysfunction and 
dopamine agonists, which appears to be independent from blood pressure–lowering 
effects, as we did not find any linkage between autonomic scores and the use of 
other medications known to lower blood pressure. 
Specifically addressing the issue of orthostatic hypotension, another study showed a 
much higher rate (58% of 91 patients had a systolic blood pressure fall of 20 mm Hg) 
than we did, but their disease duration was longer (7 years), all their patients were 
receiving l-dopa, and they were receiving it at higher doses (mean daily dose 682 
mg) than our cases.[23] Our finding that less than a quarter of patients reporting 
syncope had an objective drop in blood pressure is in keeping with a previous 
study.[24] This presumably relates to transient drops in blood pressure, which are 
not captured at every clinic visit, because they can be remote in timing from previous 
syncopal events. This can make it difficult to establish a consistent relationship 
between syncope (identified by history) and orthostatic hypotension (confirmed on 
examination). However, both are important risk factors for fall-related physical 
injuries.[25] Further, orthostatic hypotension can be a key marker of autonomic 
dysfunction. In one study of patients with PD (and dementia with Lewy bodies), those 
with persistent orthostatic hypotension had a significantly shorter survival compared 
to those with no or nonpersistent orthostatic hypotension. Patients with constipation 
and/or urinary incontinence, in addition to persistent orthostatic hypotension, had a 
poorer prognosis compared to those with isolated persistent orthostatic hypotension 
or no orthostatic hypotension.[26] The presence of orthostatic hypotension is 
reported to influence certain domains of cognitive function in PD such as 
attention.[27] Although exact pathological correlations have not been established, α-
synuclein accumulation in the central and peripheral autonomic nervous systems as 
well as in neocortical areas is generally believed to be a link between autonomic 
dysfunction and cognitive decline in PD.[28] The negative correlation between the 
presence of orthostatic hypotension and cognitive scores that we found is consistent 
with that hypothesis, and the associations with both daytime sleepiness and 
nighttime sleep disturbance, are of potential significance. We intend to analyze these 
prognostic indicators in longer-term follow-up of our cohort. 
Sweating dysfunction was more than twice as common in another small study (64% 
of 77 cases), compared to our series, but their cases had a mean disease duration of 
more than 12 years, and the relationship was strongest between motor fluctuations 
(both “off” periods and dyskinesia) and sweating episodes,[29] in contrast with our 
study at a much earlier disease stage when motor fluctuations are uncommon. 
Constipation is a recognized prodromal feature of PD[30] but more than half of our 
cases did not report this, which implies limited sensitivity in the prodromal phase, for 
this is as an early nonmotor feature.[31] Gastrointestinal symptoms that occur more 
frequently in PD than controls are sialorrhea, dysphagia, nausea, constipation, and 
defecatory dysfunction.[32] This is likely to reflect direct involvement of the myenteric 
plexus with Lewy body pathology. Comparison of our findings to previous reports is 
inexact because of longer disease duration in earlier reports,[32] but the rank order 
and frequency of key symptoms such as sialorrhea, constipation, dysphagia, and 
fecal incontinence in our study was similar to one large study at around 7 years' 
disease duration.[33] This raises the question as to whether or not such 
gastrointestinal features evolve significantly with time, or alternatively reflect long-
standing pathological changes that emerge long before motor features of PD appear, 
and have a very slow progression rate.[34] 
The severity of autonomic dysfunction in our study of recently diagnosed cases of 
PD correlated with motor severity, other nonmotor features, and quality-of-life 
scores. This is not surprising, as previous studies assessing various subdomains of 
autonomic function also found positive correlations with disease severity and quality-
of-life measures.[21, 23, 29, 32] In a study to evaluate the relative frequency and 
comparative impact of all NMS on health-related quality-of-life scores, not only were 
autonomic symptoms the most common NMS reported by patients, but the health-
related quality of life correlated most strongly with these symptoms.[35] The 
strongest correlation we found between the SCOPA-AUT and other clinimetric 
variables was with NMSS scores. Although both SCOPA-AUT and NMSS are global 
scales for assessing autonomic symptoms, when more detailed measures are 
required for assessing specific domains of autonomic function, such as sialorrhea, 
dysphagia, or constipation, more specific scales for individual symptoms might be 
required.[36] 
Diagnostic accuracy is a key consideration, and it is particularly relevant to the 
assessment of autonomic features related to PD, as the inclusion of MSA cases 
would exaggerate the findings. A greater autonomic symptom burden is expected in 
MSA than in PD, and it is reflected by higher SCOPA-AUT scores, which are based 
on more bowel and urinary problems.[22]For this reason, we defined our main 
analysis group as PD cases without any unusual or atypical features, and we 
examined the extent to which clinicians appeared to be influenced by autonomic 
features in their categorization of the cases that were excluded from the main 
analysis. Such atypical cases showed significantly higher autonomic scores, both 
“total” and in the gastrointestinal and urinary domains, and they also had greater 
motor severity and were more likely to have postural instability and a gait difficulty 
phenotype. This suggests that the practicing clinician must recognize a mix of motor 
and nonmotor features that are potentially challenging to the diagnosis of PD. If a 
significant proportion of these “possibly atypical” cases are correctly diagnosed as 
PD, then we will have somewhat underestimated the autonomic system components 
of early PD. On the other hand, cases may later turn out to be MSA may be present 
in our group without atypical features at the time of assessment. In considering the 
balance of these issues, 4.8% of our cohort (91 of 1914 cases) had possibly unusual 
or atypical clinical features. Inclusion of a qualitative component regarding diagnostic 
accuracy may be useful in helping to understand the findings from pathological 
studies that consistently report a proportion of MSA cases among patients labeled as 
PD in life.[4, 5, 7, 37] Early diagnostic accuracy in both PD and MSA is critical to 
research advances,[4] but this may require the discovery of biomarkers rather than 
the more rigid application of clinical diagnostic criteria, noting the overlap in 
autonomic and other features between the “entirely typical” and “less typical” PD 
cases. Although our study predated the most recent consensus regarding PD 
diagnosis,[38] our follow-up assessments will encompass these criteria. 
The present report represents the largest study (n > 1700) to date examining the 
issue of autonomic dysfunction in PD at an early PD stage. The large study size 
increased our ability to detect small differences between groups, and some of these 
differences may not be clinically significant. Considering the potential bias of motor 
state (“on” versus “off” when motor scoring was assessed at clinic visits), the 
proportion of treated patients in an “off” state was 5.3%, so this is unlikely to have 
influenced our interpretation significantly. 
In addition, a limitation of most studies performed at an early stage of PD is the lack 
of autopsy data. In the current study the diagnosis of PD was based on clinical 
expert opinion without histopathological confirmation given the early stage at which 
patients were recruited to the study. The validity of our interpretation will be 
reassessed as we continue to follow these cases, which includes consent for 
autopsy. Another limitation was the use of questionnaire-based diagnostic criteria for 
RBD, hyposmia, and depression without the use of laboratory testing or psychiatric 
assessment. 
In conclusion, autonomic symptoms are present in a majority of people with early 
PD, and these correlate with other markers of disease severity and an impaired 
quality of life. Our study highlights the extent to which we may expect to see 
autonomic features in early PD, and the relationship between autonomic features 
and diagnostic certainty, highlighting the importance of the balanced diagnostic 
judgment approach advocated in the recent consensus guidelines.[38] 
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